These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32842436)

  • 1. [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):513-521. PubMed ID: 32842436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].
    Xue LY; Li Y; Huang J; ; ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):291-297. PubMed ID: 37078210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
    Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
    Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
    Song P; Cui X; Bai L; Zhou X; Zhu X; Zhang J; Jin F; Zhao J; Zhou C; Zhou Y; Zhang X; Wang K; Wang Q; Yu Y; Zhang X; Bai C; Zhang L
    Thorac Cancer; 2019 May; 10(5):1303-1309. PubMed ID: 31016875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
    ;
    Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
    Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
    Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
    Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
    Zhou C; Wang J; Bu H; Wang B; Han B; Lu Y; Wang Z; Zhu B; Wang Z; Song Q; Ren S; Lin D; He Y; Hu X; Zhao H; Qin S
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):65-76. PubMed ID: 32093450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Bravaccini S
    Lung Cancer; 2019 Jun; 132():152-153. PubMed ID: 30879776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer].
    Chen G; Song X
    Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):697-702. PubMed ID: 30201070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
    Wu S; Hu C; Wu F; Wu Y; Liu P
    Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.